Checked.be
Active
BE 1014.594.561Private limited company
Dr. J. Cornette
Burgemeester J.Cardonstraat 11 ·9070 Destelbergen, Belgium· 1 yrs active
Conclusion
Dr. J. Cornette has been active since 2024 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €143k and a net result of €111k. The computed 12-month bankruptcy probability is 1.4% (low).
Based on the State Gazette, CBE and 2 annual accounts.
Key figures
| Equity | €143k |
| Net result | €111k |
| Active | 1 yrs |
| Locations | 1 |
Financial profile
92
/ 100
Exceptional profile, strong across almost every axis.
All 5 axes are computed from data Checked has read.
Health
100
Profitability
100
Solvency
100
Growth
78
Stability
82
Bankruptcy probability (12 mo)
Risk Assessment
0 / 100
Low riskTrust signals
Young company
Founded in 2024, under 3 years, statistically higher risk.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Checked score
100
/ 100
Excellent
Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.
Indicative credit limit
€14k
estimate, not credit advice
Score history
83
2024
100
2025
purely financial, excl. current insolvency signals
Score components
Liquidity
Current ratio 8.19 (≥ 1.5)
+10
Quick ratio
Quick ratio 8.19 (≥ 1.0)
+5
Leverage
Debt/equity 0.44 (< 1.0)
+10
Profitability
ROE 77% (≥ 10%)
+10
Interest coverage
Interest coverage 62.0× (≥ 3×)
+8
Profit trend
Net profit up YoY
+5
Equity growth
Equity growing YoY
+3
Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.
Financial overview
Annual accounts filed on 29-06-2026 with the NBB · fiscal year 2025 · micro schema
€159k
+321.5%
24-25
€111k
+270.1%
24-25
€126k
+320.3%
24-25
€206k
+78.6%
24-25
€143k
+341.5%
24-25
€123k
+583.7%
24-25
€32k
+309.0%
24-25
€63k
-24.2%
24-25
€17k
-26.4%
24-25
€46k
-23.4%
24-25
8.19
+361.7%
24-25
8.19
+361.7%
24-25
69.5%
+147.2%
24-25
0.44
-82.8%
24-25
77.4%
-16.2%
24-25
53.8%
+107.2%
24-25
61.99
-83.2%
24-25
Figures by fiscal year and ratios
| Fiscal year | 2025 | 2024 |
|---|---|---|
| Deposit | micro schema | micro schema |
| Revenue | - | - |
| EBITDA | €159k | €38k |
| Net profit | €111k | €30k |
| Cash flow | €126k | €30k |
| Staff costs | - | - |
| Income taxes | €32k | €8k |
| Dividends | - | - |
| Total assets | €206k | €115k |
| Equity | €143k | €32k |
| Debt | €63k | €83k |
| of which ≤ 1y | €17k | €23k |
| of which > 1y | €46k | €60k |
| Working capital | €123k | €18k |
| Employees (FTE) | - | - |
Ratios (computed)
| 2025 | 2024 | |
|---|---|---|
| Current ratio | 8.19 | 1.77 |
| Quick ratio | 8.19 | 1.77 |
| Working capital ratio | 59.5% | 15.5% |
| Solvency | 69.5% | 28.1% |
| Debt / equity | 0.44 | 2.56 |
| Long-term debt ratio | 0.32 | 1.84 |
| Interest coverage | 61.99 | 368.81 |
| Gross margin | - | - |
| Net margin | - | - |
| ROA | 53.8% | 25.9% |
| ROE | 77.4% | 92.3% |
| EBITDA margin | - | - |
| Days sales outstanding | - | - |
| Days payable outstanding | - | - |
| Inventory turnover | - | - |
| Days inventory (DSI) | - | - |
Balance-sheet composition 2025
Full annual accounts (23 line items)
Filed balance sheet and income statement, exactly as deposited with the NBB.
| Line item | Code | 2025 | 2024 |
|---|---|---|---|
| Balance sheet, Assets | |||
| TOTAL ASSETS | 20/58 | €206k | €115k |
| Fixed assets | 21/28 | €66k | €74k |
| Tangible fixed assets | 22/27 | €66k | €74k |
| Current assets | 29/58 | €140k | €41k |
| Amounts receivable within one year | 40/41 | €30k | €1k |
| Investments | 50/53 | €74k | - |
| Cash & bank | 54/58 | €30k | €36k |
| Balance sheet, Equity & liabilities | |||
| TOTAL EQUITY & LIABILITIES | 10/49 | €206k | €115k |
| Equity | 10/15 | €143k | €32k |
| Contributions / capital | 10/11 | €3k | €3k |
| Reserves | 13 | €141k | €30k |
| Amounts payable | 17/49 | €63k | €83k |
| Amounts payable after one year | 17 | €46k | €60k |
| Amounts payable within one year | 42/48 | €17k | €23k |
| Trade debts payable within one year | 44 | €706 | €628 |
| Income statement | |||
| Gross operating margin | 9900 | €159k | €38k |
| Operating result | 9901 | €144k | €38k |
| Financial income | 75 | €826 | €3 |
| Financial charges | 65 | €3k | €103 |
| Result before taxes | 9903 | €142k | €38k |
| Income taxes | 67/77 | €32k | €8k |
| Net result for the period | 9904 | €111k | €30k |
| Result to be appropriated | 9905 | €111k | €30k |
Legal Structure
| NACE primary | - |
| Legal form | Private limited company(610) |
| Incorporation | 03-10-2024 |
| Status | Active |
| Postal code | 9070 |
Establishment units
Burgemeester J.Cardonstraat 11, 9070 Destelbergen
since 20242.364.959.473
Real-estate footprint
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 44013B0617/00B000 | Flanders | 298 m² | 1 · 88 m² | 7.8 m |
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Updates
Next filing, fiscal year 2026, expected by
2026
29-06
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2025
31-12
Financial
Liquidity times 5current ratio 8.19
Current ratio from 1.77 to 8.19; short-term debt falls from €23k to €17k.
31-12
Financial
Equity above €100kEq €143k ▲342%
2 profitable years in a row build equity to €143k.
05-09
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema · 36 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Belgian State Gazette reading coverage
We know of 1 Belgian State Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Credit advice
Company registry (CBE)
Names & trade names
| Legal nameNL | Dr. J. Cornette |